Targets › COL4A1
1 program from 1 company in 6 trials: 5 Phase 4, 1 Phase 3; Genitourinary, Other; next expected readout Dec 2027.
Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen..; FUNCTION: Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. (UniProt, P02462)
Open in Phaseline: the race on COL4A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Endo USA Inc., a Keenova Therapeutics Company | Collagenase Clostridium Histolyticum (KN3835) Collagen hydrolytic enzyme | COL1A2, COL1A1, COL2A1, COL3A1, COL4A1 | Phase 3 | Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger … | Dec 2027 |
Peyronie Disease (2) Flexible Hammertoe (1) Peyronie's Disease (1) Dupuytren Disease of Finger (1) Dupuytren Contracture (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.